The US National Cancer Institute (NCI) performed the first-in-human clinical trial using T-cells expressing an anti-BCMA CAR (11 D5–3-CD828 Z) in MM [18]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.